Reducing the Risk in a Risk-Based Portfolio
The Next Big Catalyst for Stocks/Commodities? Military Conflict
Innovus Puts Spotlight on Sexual Health with Innovative Supplement Portfolio
Housing Prices Rise 5.3%; Are The Good Old Days Back?
This Election is America's First Presidential Unpopularity Contest
Neil Belenkie of Sirona Biochem Corp. (SBM) chats about their company's development of drug compounds for the treatments of type 2 diabetes and obesity with Equities.com
You have to be logged in to leave a comment.
I'm sorry, but in order to complete what you're trying to do, you must be logged in.
© 2016 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).